INBX - CIK 0001739614
Inhibrx, Inc. trades as INBX and has a market capitalization of $1.53 B, making it the #2302 largest US-listed company by market value. This page tracks Inhibrx, Inc. through 261 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 4 fiscal years Inhibrx, Inc.'s revenue declined from $13.21M to $1.80M, a compound annual decline rate of 39.2%. Net profit margin compressed from -389.1% to -13408.9% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Passive ownership stake (update) | SC 13G/A | 2024-11-14 |
| 15-12G | - | 2024-06-10 |
| Passive ownership stake (update) | SC 13G/A | 2024-06-03 |
| Insider trade | 4 | 2024-06-03 |
| Insider trade | 4 | 2024-05-31 |
| Delisting notice | 25-NSE | 2024-05-30 |
| S-8 POS | - | 2024-05-30 |
| S-8 POS | - | 2024-05-30 |
Recent Corporate Highlights and Upcoming Milestones
The largest companies sharing Inhibrx, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Inhibrx, Inc. (INBX) has a market capitalization of $1.53 B as of 2026-05-29, ranking #2302 among US-listed companies.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.